Millions use GLP-1 medications like Ozempic, Wegovy, and Zepbound for weight loss-but what happens when they stop?
Previous clinical trials warned of rapid weight regain. However, new real-world data from Cleveland Clinic tells a more optimistic story.
The study tracked nearly 8,000 adults in Ohio and Florida who used semaglutide or tirzepatide for three to 12 months before discontinuing treatment.
Patients treated for obesity lost an average of 8.4% of their body weight before stopping. One year later, they had regained just 0.5% on average.
Lead author Dr. Hamlet Gasoyan attributes this to continued care: 27% switched to other obesity medications, 20% restarted their original drug, and 14% enrolled in intensive lifestyle programs with dietitians and fitness specialists.
Unlike rigid clinical trials where patients receive no follow-up support, real-world patients often stay engaged with the healthcare system-blunting the feared “rebound” effect.
Researchers caution the findings reflect outcomes from one integrated health system and may not apply nationwide. Some weight changes could also stem from unmeasured interventions.
Future research will compare alternative obesity treatments for those discontinuing GLP-1 therapy to guide clinical decisions.